Conflict of interest
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
Article first published online: 21 FEB 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 3, pages 333–337, March 2014
How to Cite
Mattei, P.L., Corey, K.C. and Kimball, A.B. (2014), Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology, 28: 333–337. doi: 10.1111/jdv.12106
PLM received partial funding from the National Psoriasis Foundation and Janssen. ABK is an investigator and consultant to Abbvie, Janssen, and Amgen and has fellowship funding from Janssen. She also has been an investigator and consultant to Pfizer, VBL, Merck, Celgene, Idera and consultant to Lilly and Moleculin.
National Psoriasis Foundation Grant.
- Issue published online: 19 FEB 2014
- Article first published online: 21 FEB 2013
- Manuscript Accepted: 15 JAN 2013
- Manuscript Received: 30 JUL 2012
Multiple metrics evaluate the efficacy of psoriasis treatment, but interestingly, the correlation between the mostly widely used clinical trial efficacy end point, the physician-rendered Psoriasis Area Severity Index PASI score and, the most widely used quality of life metric, the Dermatology Life Quality Index DLQI, is not always high.
To perform a systematic review to determine PASI to DLQI correlation.
RCTs of biological agents for the treatment of moderate-to-severe psoriasis were reviewed in accordance with PRISMA guidelines. The mean percentage PASI improvement and change in mean DLQI values were recorded and compared for treatment groups from baseline to 10–16 weeks of therapy.
A search of the literature yielded 155 sources, of which 13 RCTs met inclusion and exclusion criteria. Percentage of PASI improvement from baseline correlates with DLQI changes with an r2 value of 0.80 from baseline through weeks 10–16. When grouped by mean percentage reduction in PASI, agents demonstrating >75% mean reduction in PASI demonstrated a mean DLQI improvement over agents that achieved <75%–50% mean reduction in PASI or <50% mean reduction in PASI [minimal clinically important difference (MCID) 3.2]. In addition, a reduction in mean PASI of at least 75%, predicted a mean movement from DLQI band 3 to DLQI band 1, in all nine treatment arms demonstrating such efficacy.
Mean PASI and DLQI correlate predictably in patients with chronic moderate-to-severe plaque psoriasis undergoing treatment with biological agents. A reduction in PASI of at least 75% can translate to significant quality-of-life improvement in patients treated with these therapies.